REG - e-Therapeutics plc - Notification of Full Year Results Date

E-TherapeuticsAnnouncement

27/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230427:nRSa5249Xa&default-theme=true

RNS Number : 5249X  e-Therapeutics plc  27 April 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Notification of Full Year Results Date

 

 

London, UK, 27 April 2023- e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, will announce its full year audited results
for the year ended 31 January 2023 on Thursday 04 May 2023.

 

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Laura Roca-Alonso, COO                                                             www.etherapeutics.co.uk

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary HepNetÔ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmicÔ, ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNetÔ.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
across a variety of high unmet therapeutic needs in cardiometabolic
indications and promising hepatocyte- expressed targets with extra-hepatic
effects in other disease areas. ETX has also partnered with biopharma
companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using
its computational network biology approach across a diverse range of drug
discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGRGDSUSDDGXL